trending Market Intelligence /marketintelligence/en/news-insights/trending/69ggHsRLVFcNHgA_MfGGmA2 content esgSubNav
In This List

XTL Biopharmaceuticals regains compliance with Nasdaq listing rule

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


XTL Biopharmaceuticals regains compliance with Nasdaq listing rule

XTL Biopharmaceuticals Ltd. regained compliance with the minimum $2.5 million stockholders' equity requirement for continued listing on the Nasdaq Capital Market.

Nasdaq determined that the company is compliant with the listing rule after XTL showed that it had stockholders' equity of about $3.6 million as of Sept. 30.